156 related articles for article (PubMed ID: 7075643)
1. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.
Hallengren B; Nilsson OR; Karlberg BE; Melander A; Tegler L; Wåhlin-Boll E
Eur J Clin Pharmacol; 1982; 21(5):379-84. PubMed ID: 7075643
[TBL] [Abstract][Full Text] [Related]
2. Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine.
Kirch W; Spahn H; Köhler H; Ohnhaus EE; Mutschler E
Klin Wochenschr; 1982 Nov; 60(22):1401-7. PubMed ID: 7176462
[TBL] [Abstract][Full Text] [Related]
3. Interaction of cimetidine with metoprolol, propranolol, or atenolol.
Kirch W; Köhler H; Spahn H; Mutschler E
Lancet; 1981 Sep; 2(8245):531-2. PubMed ID: 6115283
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients.
Okamura Y; Shigemasa C; Tatsuhara T
Endocrinol Jpn; 1986 Oct; 33(5):605-15. PubMed ID: 3830069
[TBL] [Abstract][Full Text] [Related]
5. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.
Tateishi T; Nakashima H; Shitou T; Kumagai Y; Ohashi K; Hosoda S; Ebihara A
Eur J Clin Pharmacol; 1989; 36(1):67-70. PubMed ID: 2917591
[TBL] [Abstract][Full Text] [Related]
6. Determination of the new beta-blocker bisoprolol and of metoprolol, atenolol and propranolol in plasma and urine by high-performance liquid chromatography.
Bühring KU; Garbe A
J Chromatogr; 1986 Oct; 382():215-24. PubMed ID: 2878004
[TBL] [Abstract][Full Text] [Related]
7. Effects of thyroid dysfunction on propranolol kinetics.
Riddell JG; Neill JD; Kelly JG; McDevitt DG
Clin Pharmacol Ther; 1980 Nov; 28(5):565-74. PubMed ID: 7438675
[TBL] [Abstract][Full Text] [Related]
8. Influence of ranitidine on plasma metoprolol and atenolol concentrations.
Spahn H; Mutschler E; Kirch W; Ohnhaus EE; Janisch HD
Br Med J (Clin Res Ed); 1983 May; 286(6377):1546-7. PubMed ID: 6133576
[No Abstract] [Full Text] [Related]
9. Enhancement of the bioavailability of propranolol and metoprolol by food.
Melander A; Danielson K; Scherstén B; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):108-12. PubMed ID: 872491
[TBL] [Abstract][Full Text] [Related]
10. Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients.
Nilsson OR; Melander A; Tegler L
Eur J Clin Pharmacol; 1980 Oct; 18(4):315-20. PubMed ID: 7439251
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of methimazole in humans.
Hengstmann JH; Hohn H
Klin Wochenschr; 1985 Dec; 63(23):1212-7. PubMed ID: 3841378
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and clinical effects of atenolol in therapy of hyperthyroidism.
Geffner DL; Sladek J; Hershman JM
Drugs Exp Clin Res; 1990; 16(4):167-73. PubMed ID: 2076652
[TBL] [Abstract][Full Text] [Related]
13. Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrillation threshold: comparison with atenolol, propranolol, and pindolol.
Coram WM; Olson RW; Beil ME; Cabot CF; Weiss GB
J Cardiovasc Pharmacol; 1987 May; 9(5):611-21. PubMed ID: 2439844
[TBL] [Abstract][Full Text] [Related]
14. Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects.
Shiga T; Fujimura A; Tateishi T; Ohashi K; Ebihara A
J Clin Pharmacol; 1993 Aug; 33(8):756-61. PubMed ID: 8408738
[TBL] [Abstract][Full Text] [Related]
15. Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism.
Perrild H; Hansen JM; Skovsted L; Christensen LK
Clin Endocrinol (Oxf); 1983 Feb; 18(2):139-42. PubMed ID: 6133659
[TBL] [Abstract][Full Text] [Related]
16. High-performance liquid chromatographic method for the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue.
Winkler H; Ried W; Lemmer B
J Chromatogr; 1982 Mar; 228():223-34. PubMed ID: 7076746
[TBL] [Abstract][Full Text] [Related]
17. beta-Adrenoreceptor-blocking agents and the blood-brain barrier.
Cruickshank JM; Neil-Dwyer G; Cameron MM; McAinsh J
Clin Sci (Lond); 1980 Dec; 59 Suppl 6():453s-455s. PubMed ID: 7449299
[TBL] [Abstract][Full Text] [Related]
18. Gas chromatographic-mass spectrometric differentiation of atenolol, metoprolol, propranolol, and an interfering metabolite product of metoprolol.
Angier MK; Lewis RJ; Chaturvedi AK; Canfield DV
J Anal Toxicol; 2005 Sep; 29(6):517-21. PubMed ID: 16168172
[TBL] [Abstract][Full Text] [Related]
19. Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat.
Belpaire FM; de Smet F; Vynckier LJ; Vermeulen AM; Rosseel MT; Bogaert MG; Chauvelot-Moachon L
J Pharmacol Exp Ther; 1990 Jul; 254(1):116-22. PubMed ID: 2366179
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states.
Jacobs G; Whittem T; Sams R; Calvert C; Ferguson D
Am J Vet Res; 1997 Apr; 58(4):398-403. PubMed ID: 9099387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
